

Vivian Lui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917972/publications.pdf>

Version: 2024-02-01

129
papers

7,095
citations

66234

42
h-index

62479

80
g-index

132
all docs

132
docs citations

132
times ranked

9590
citing authors

#	ARTICLE	IF	CITATIONS
1	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	18.1	1,649
2	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. <i>Cancer Discovery</i> , 2013, 3, 761-769.	7.7	505
3	TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. <i>Cancer Research</i> , 2012, 72, 3270-3281.	0.4	252
4	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. <i>Nature Communications</i> , 2017, 8, 14121.	5.8	227
5	STAT3 as a therapeutic target in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 231-241.	1.4	212
6	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	1.1	191
7	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2015, 126, 169-180.	3.9	156
8	Phosphorylation of TNF- α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6901-6906.	3.3	130
9	Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3473-82.	3.3	127
10	Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 375.	1.1	125
11	Microneedle-Mediated Delivery of Lipid-Coated Cisplatin Nanoparticles for Efficient and Safe Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 33060-33069.	4.0	125
12	Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. <i>Cancer Letters</i> , 2014, 349, 15-25.	3.2	99
13	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. <i>Molecular Cancer Research</i> , 2014, 12, 571-582.	1.5	94
14	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. <i>Clinical Cancer Research</i> , 2013, 19, 380-392.	3.2	90
15	Translational genomics of nasopharyngeal cancer. <i>Seminars in Cancer Biology</i> , 2020, 61, 84-100.	4.3	90
16	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1114-1119.	3.3	86
17	Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 541-551.	1.8	82
18	Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. <i>Oncogene</i> , 2003, 22, 6183-6193.	2.6	78

#	ARTICLE	IF	CITATIONS
19	Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. <i>BMC Cancer</i> , 2013, 13, 619.	1.1	76
20	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1414-1424.	1.9	73
21	Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e62284.	1.1	69
22	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i> . <i>International Journal of Cancer</i> , 2009, 125, 1884-1893.	2.3	67
23	Microneedles loaded with anti-PD-1 cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. <i>Nanoscale</i> , 2020, 12, 18885-18898.	2.8	67
24	Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and <i>in vivo</i> tumor formation ability of nasopharyngeal carcinoma cells. <i>Carcinogenesis</i> , 2009, 30, 2085-2094.	1.3	66
25	Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting. <i>Clinical Cancer Research</i> , 2008, 14, 7682-7690.	3.2	65
26	Gastrin-Releasing Peptide Receptor-Mediated Autocrine Growth in Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2002, 94, 375-383.	3.0	63
27	Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1. <i>Molecular Pharmacology</i> , 2007, 71, 1435-1443.	1.0	63
28	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, 1235-1242.	0.8	63
29	EGFR-mediated cell cycle regulation. <i>Anticancer Research</i> , 2002, 22, 1-11.	0.5	62
30	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. <i>Neoplasia</i> , 2015, 17, 256-264.	2.3	59
31	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , 2010, 28, 413-420.	1.2	58
32	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	1.2	56
33	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 602.	1.1	56
34	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- κ B activation and immune escape. <i>Nature Communications</i> , 2021, 12, 4193.	5.8	56
35	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. <i>Oncogene</i> , 2011, 30, 1127-1134.	2.6	55
36	Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. <i>Neoplasia</i> , 2005, 7, 426-431.	2.3	51

#	ARTICLE	IF	CITATIONS
37	Targeting tumor hypoxia in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2013, 35, 133-145.	0.9	51
38	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. <i>PLoS ONE</i> , 2015, 10, e0135750.	1.1	51
39	The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 743-744, 78-88.	0.4	50
40	Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air Pollution. <i>Chinese Journal of Cancer</i> , 2014, 33, 476-80.	4.9	50
41	Proteomic Characterization of Head and Neck Cancer Patientâ€œDerived Xenografts. <i>Molecular Cancer Research</i> , 2016, 14, 278-286.	1.5	48
42	The <i>RARS</i> â€œ <i>MAD1L1</i> Fusion Gene Induces Cancer Stem Cellâ€œlike Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 659-673.	3.2	47
43	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 238.	3.4	44
44	Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2018, 10, 210.	1.7	43
45	Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2003, 24, 1705-1712.	1.3	41
46	Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 221-232.	2.0	41
47	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. <i>Investigational New Drugs</i> , 2010, 28, 326-333.	1.2	40
48	KIAA0495/PDAM Is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. <i>Brain Pathology</i> , 2010, 20, 1021-1032.	2.1	40
49	Prediction of radiotherapy response with a 5â€œmicroRNA signatureâ€œbased nomogram in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 726-735.	1.3	40
50	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. <i>Investigational New Drugs</i> , 2013, 31, 567-575.	1.2	38
51	JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against <i>MYCN</i> -amplified small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 86312-86324.	0.8	37
52	A small molecule inhibitor of NF- κ B, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. <i>Cancer Letters</i> , 2010, 287, 23-32.	3.2	36
53	Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. <i>Journal of Gene Medicine</i> , 2001, 3, 384-393.	1.4	34
54	The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3425.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor. <i>Human Gene Therapy</i> , 2002, 13, 177-185.	1.4	30
56	STAT3 as a therapeutic target for Epstein-Barr virus (EBV) -associated nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2013, 330, 141-149.	3.2	30
57	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , 2014, 343, 24-32.	3.2	30
58	Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2003, 9, 5028-35.	3.2	30
59	FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. <i>Cancer Letters</i> , 2011, 304, 97-106.	3.2	29
60	Specific Down-regulation of HER-2/neu Mediated by a Chimeric U6 Hammerhead Ribozyme Results in Growth Inhibition of Human Ovarian Carcinoma. <i>Molecular Therapy</i> , 2001, 3, 169-177.	3.7	28
61	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. <i>Biochemical Pharmacology</i> , 2010, 79, 1772-1780.	2.0	28
62	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2011, 29, 1123-1131.	1.2	28
63	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	2.0	28
64	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. <i>Life Science Alliance</i> , 2020, 3, e201900545.	1.3	27
65	Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer. <i>Journal of Proteome Research</i> , 2010, 9, 3073-3082.	1.8	26
66	TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. <i>Oncology Letters</i> , 2015, 9, 569-574.	0.8	26
67	The cylindromatosis (CYLD) gene and head and neck tumorigenesis. <i>Cancers of the Head & Neck</i> , 2016, 1, 10.	6.2	23
68	Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. <i>Oncolmmunology</i> , 2018, 7, e1388484.	2.1	23
69	A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy. <i>Current Cancer Drug Targets</i> , 2015, 15, 327-336.	0.8	22
70	Precision drugging of the MAPK pathway in head and neck cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 20.	1.7	22
71	Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. <i>Investigational New Drugs</i> , 2011, 29, 401-410.	1.2	21
72	K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2012, 30, 48-58.	1.2	21

#	ARTICLE	IF	CITATIONS
73	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , 2010, 79, 842-852.	2.0	20
74	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	0.4	20
75	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2011, 29, 1241-1252.	1.2	17
76	Mesenchymal stem cells participate in oral mucosa carcinogenesis by regulating T cell proliferation. <i>Clinical Immunology</i> , 2019, 198, 46-53.	1.4	15
77	miR-466 is putative negative regulator of Coxsackie virus and Adenovirus Receptor. <i>FEBS Letters</i> , 2015, 589, 246-254.	1.3	14
78	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 262.	3.5	13
79	Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20. <i>Communications Biology</i> , 2020, 3, 234.	2.0	13
80	Potential of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. <i>Gene Therapy</i> , 1998, 5, 1462-1471.	2.3	12
81	Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Pharmacology</i> , 2008, 73, 627-638.	1.0	12
82	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1417-1425.	1.1	12
83	Hypermethylation of NF- κ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	1.1	12
84	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1107.	1.1	12
85	Emerging Roles of ALK in Immunity and Insights for Immunotherapy. <i>Cancers</i> , 2020, 12, 426.	1.7	12
86	Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 106486-106498.	0.8	12
87	FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. <i>Oncogene</i> , 2011, 30, 1518-1530.	2.6	11
88	Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer. <i>Head and Neck Pathology</i> , 2012, 6, 91-97.	1.3	11
89	Effects of Salivary Mg on Head and Neck Carcinoma via TRPM7. <i>Journal of Dental Research</i> , 2019, 98, 304-312.	2.5	11
90	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. <i>EBioMedicine</i> , 2021, 65, 103242.	2.7	10

#	ARTICLE	IF	CITATIONS
91	Induction of laryngeal cancer cell death by Entâ€hydroxyâ€kaurâ€enâ€ic acid. <i>Head and Neck</i> , 2010, 32, 1506-1518.	0.9	9
92	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , 2013, 31, 30-38.	1.2	9
93	An update of ALK inhibitors in human clinical trials. <i>Future Oncology</i> , 2016, 12, 71-81.	1.1	9
94	Case Report: Exome sequencing reveals recurrent RETSAT mutations and a loss-of-function POLDIP2 mutation in a rare undifferentiated tongue sarcoma. <i>F1000Research</i> , 2018, 7, 499.	0.8	9
95	<i>Andrographis paniculata</i> elicits anti-invasion activities by suppressing TM4SF3 gene expression and by anoikis-sensitization in esophageal cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 3570-87.	1.4	9
96	Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma. <i>Npj Genomic Medicine</i> , 2020, 5, 17.	1.7	8
97	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. <i>Oncotarget</i> , 2016, 7, 23300-23311.	0.8	8
98	Fullâ€length Mst1 exhibits growth promoting function in human hepatocellular carcinoma cells. <i>FEBS Letters</i> , 2013, 587, 496-503.	1.3	7
99	Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey. <i>JCO Oncology Practice</i> , 2020, 16, e770-e778.	1.4	7
100	Identification of Mutations in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e85619.	1.1	6
101	Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma. <i>Clinical Immunology</i> , 2018, 191, 27-33.	1.4	5
102	Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 52-64.	1.5	5
103	Combinations of proteasome inhibitors with obatoclox are effective for small cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2020, 42, 1298-1310.	2.8	5
104	Germline mutation and aberrant transcripts of <i>WWOX</i> in a syndrome with multiple primary tumors. <i>Journal of Pathology</i> , 2019, 249, 19-25.	2.1	4
105	Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. <i>Cancers</i> , 2020, 12, 2935.	1.7	4
106	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. <i>PLoS ONE</i> , 2016, 11, e0166185.	1.1	4
107	An update on genomic-guided therapies for pediatric solid tumors. <i>Future Oncology</i> , 2017, 13, 1345-1358.	1.1	2
108	Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epsteinâ€Barr virus in situ assays. <i>Cancer</i> , 2018, 124, 434-435.	2.0	2

#	ARTICLE	IF	CITATIONS
109	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines. Cancer Research, 2012, 72, 4602-4602.	0.4	2
110	Hong Kong releases Copyright (Amendment) Bill 2006. Computer Law and Security Review, 2006, 22, 418-420.	1.3	1
111	Abstract 1373: Preclinical activity of axitinib and its associated change of serum biomarkers in nasopharyngeal carcinoma (NPC). , 2012, , .		1
112	Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer.. , 2013, , .		1
113	Abstract 646: Targeting MHC class I molecules and immune checkpoints as key immune evasion strategies in EBV-associated nasopharyngeal carcinoma. , 2017, , .		1
114	Abstract 4033:RAC1genomic aberrations as predictive biomarkers for head and neck squamous cell carcinoma (HNSCC). , 2019, , .		1
115	Abstract 2527: Genomic aberrations of <i>ALK</i> in head and neck squamous cell carcinoma. Cancer Research, 2019, 79, 2527-2527.	0.4	1
116	Abstract 3088: Mammalian sterile-20 like kinase 1(Mst1) upregulates cyclin D1 to promote hepatocellular carcinoma cell growth. , 2010, , .		0
117	Abstract 1006: TP53-induced glycolysis and apoptosis regulator (TIGAR) induces NADPH production and growth in nasopharyngeal carcinoma cells. , 2011, , .		0
118	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0
119	Abstract 2037: Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. , 2012, , .		0
120	Abstract 4668: Antitumor efficacy of AZD1480 in head and neck squamous cell carcinoma.. , 2013, , .		0
121	Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC.. , 2013, , .		0
122	Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC. , 2014, , .		0
123	Abstract 5003: Functional significance of TIGAR expression in nasopharyngeal carcinoma. , 2014, , .		0
124	Abstract 5712: Potential clinical significance of downregulation of MAPK pathway components mRNA expression in head and neck squamous cell carcinoma (HNSCC). , 2017, , .		0
125	Abstract 4278: Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC). , 2018, , .		0
126	Abstract 5347: Somatic mutation and overexpression of anaplastic lymphoma kinase (ALK) are uncommon events in Asian head and neck cancers. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 4507: Study of CCCTC-binding factor (CTCF) genetic aberrations and dysregulation in head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0
128	Abstract 4933: RAPTOR protein overexpression is predictive of poor clinical outcomes in head and neck squamous cell carcinoma (HNSCC) patients. , 2019, , .		0
129	Abstract 98: Stromal-targeting with quercetin in patient-derived models of head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0